Clinical Trial: Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.

Brief Summary:

Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.

The investigators plan to measure these factors prior to and after bronchoscopy.

Detailed Summary: This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.
Sponsor: University of Oklahoma

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome: Volume of blood loss during the procedure [ Time Frame: 1 day ]

Original Secondary Outcome: Same as current

Information By: University of Oklahoma

Dates:
Date Received: June 24, 2009
Date Started: June 2009
Date Completion:
Last Updated: April 5, 2012
Last Verified: April 2012